I am an analytical chemist at Steno Metabolomics Laboratory, working closely with Steno Systems Medicine. I analyse biological samples using high throughput mass spectrometry methods. I specialize in both gas and liquid chromatography in the field of targeted and untargeted metabolomics.
GALAXY has the ambition, by combining unique capabilities in European institutions, to perform integrated systems modelling of multi-omics data together with clinical data. To improve understanding of alcoholic liver fibrosis, and to develop diagnostic, prevention and treatment programs.
Learn more on the Galaxy website http://livergalaxy.eu
The portal vein transports metabolites produced by the human gut microbiota directly to the liver, and these may play a role in developing several liver diseases. The project will have access to many patients and will comprehensively screen their microbiota, liver and blood. The goal is to build models that describe the gut microbiome–portal vein–liver axis and to identify biomarkers for predicting, preventing and treating metabolic liver diseases
The overall objective of INNODIA therefore is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D), by creating novel tools, such as biomarkers, disease models and clinical trial paradigms.https://innodia.eu/
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
PeRsOnalising Treatment Of diabetic Nephropathy